{"id":"https://openalex.org/W4400915955","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.6109","title":"Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC).","display_name":"Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC).","publication_year":2024,"publication_date":"2024-06-01","ids":{"openalex":"https://openalex.org/W4400915955","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.6109"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2024.42.16_suppl.6109","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.6109","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.6109","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5053039908","display_name":"Kartik Sehgal","orcid":"https://orcid.org/0000-0003-4391-6943","observed_orcids":["https://orcid.org/0000-0003-4391-6943"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kartik Sehgal","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004628111","display_name":"Ruichao Shi","orcid":"https://orcid.org/0000-0002-3779-2692","observed_orcids":["https://orcid.org/0000-0002-3779-2692"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruichao Shi","raw_affiliation_strings":["Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073744803","display_name":"\u0398\u03b5\u03bf\u03b4\u03ce\u03c1\u03b1 \u03a0\u03b1\u03c0\u03c0\u03ac","orcid":"https://orcid.org/0000-0001-5336-9117","observed_orcids":["https://orcid.org/0000-0001-5336-9117"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Theodora Pappa","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111266105","display_name":"Judy K Min","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Judy K Min","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113301093","display_name":"Liam B Oakley","orcid":"https://orcid.org/0009-0004-5090-8778","observed_orcids":["https://orcid.org/0009-0004-5090-8778"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Liam B Oakley","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114045549","display_name":"Anne O\u2019Neill","orcid":"https://orcid.org/0009-0002-7334-4560","observed_orcids":["https://orcid.org/0009-0002-7334-4560"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anne ONeill","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011988886","display_name":"Michael J. Dennis","orcid":"https://orcid.org/0000-0002-8175-5311","observed_orcids":["https://orcid.org/0000-0002-8175-5311"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael J. Dennis","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061066852","display_name":"Hari Anant Deshpande","orcid":"https://orcid.org/0000-0003-0697-9355","observed_orcids":["https://orcid.org/0000-0003-0697-9355"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hari Anant Deshpande","raw_affiliation_strings":["Yale Cancer Center, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Center, New Haven, CT","institution_ids":["https://openalex.org/I2802730090"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080875822","display_name":"Robert I. Haddad","orcid":"https://orcid.org/0000-0003-1413-0079","observed_orcids":["https://orcid.org/0000-0003-1413-0079"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert I. Haddad","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004313073","display_name":"Jochen H. Lorch","orcid":"https://orcid.org/0000-0001-9781-6548","observed_orcids":["https://orcid.org/0000-0001-9781-6548"]},"institutions":[{"id":"https://openalex.org/I111979921","display_name":"Northwestern University","ror":"https://ror.org/000e0be47","country_code":"US","type":"education","lineage":["https://openalex.org/I111979921"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jochen H. Lorch","raw_affiliation_strings":["Northwestern University, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northwestern University, Chicago, IL","institution_ids":["https://openalex.org/I111979921"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"42","issue":"16_suppl","first_page":"6109","last_page":"6109"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10329","display_name":"Thyroid Cancer Diagnosis and Treatment","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10329","display_name":"Thyroid Cancer Diagnosis and Treatment","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10293","display_name":"Thyroid Disorders and Treatments","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11728","display_name":"Thyroid and Parathyroid Surgery","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/regorafenib","display_name":"regorafenib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/medullary-thyroid-carcinoma","display_name":"medullary thyroid carcinoma","score":0.8939999938011169},{"id":"https://openalex.org/keywords/differentiated-thyroid-cancer","display_name":"differentiated thyroid cancer","score":0.8769999742507935},{"id":"https://openalex.org/keywords/radioactive-iodine-refractory-disease","display_name":"radioactive iodine-refractory disease","score":0.8669999837875366},{"id":"https://openalex.org/keywords/multikinase-inhibitor","display_name":"multikinase inhibitor","score":0.8399999737739563},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7730000019073486},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.8939999938011169},{"id":"https://openalex.org/keywords/simon-s-two-stage-design","display_name":"Simon two-stage design","score":0.7789999842643738},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6790000200271606},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.7459999918937683},{"id":"https://openalex.org/keywords/metastatic-thyroid-carcinoma","display_name":"metastatic thyroid cancer","score":0.7360000014305115},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.5590000152587891},{"id":"https://openalex.org/keywords/third-line-therapy","display_name":"third-line therapy","score":0.531000018119812},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.5619999766349792},{"id":"https://openalex.org/keywords/drug-repurposing","display_name":"drug repurposing","score":0.3529999852180481},{"id":"https://openalex.org/keywords/phase-ii-trial-results","display_name":"phase II trial results","score":0.34700000286102295}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9159102439880371},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.6668674349784851},{"id":"https://openalex.org/C2993294228","wikidata":"https://www.wikidata.org/wiki/Q13632630","display_name":"Thyroid carcinoma","level":3,"score":0.6144306063652039},{"id":"https://openalex.org/C2776248978","wikidata":"https://www.wikidata.org/wiki/Q3891664","display_name":"Regorafenib","level":4,"score":0.6108171343803406},{"id":"https://openalex.org/C2908975369","wikidata":"https://www.wikidata.org/wiki/Q1208453","display_name":"Radioactive iodine","level":3,"score":0.6004718542098999},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4896159768104553},{"id":"https://openalex.org/C526584372","wikidata":"https://www.wikidata.org/wiki/Q16399","display_name":"Thyroid","level":2,"score":0.4720887839794159},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.43724074959754944},{"id":"https://openalex.org/C2777546739","wikidata":"https://www.wikidata.org/wiki/Q33525","display_name":"Carcinoma","level":2,"score":0.42661598324775696},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4164983332157135},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.35052233934402466},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.24811068177223206},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.1763209104537964},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.07888177037239075},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2024.42.16_suppl.6109","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.6109","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.6109","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4402565881","https://openalex.org/W3084285753","https://openalex.org/W3157906857","https://openalex.org/W2600855026","https://openalex.org/W2588462967","https://openalex.org/W3032785602","https://openalex.org/W2260908918","https://openalex.org/W4410804379","https://openalex.org/W2763399157","https://openalex.org/W3167625048"],"abstract_inverted_index":{"6109":[0],"Background:":[1],"Multi-kinase":[2],"inhibitors":[3],"show":[4],"activity":[5],"in":[6,44,108,137,147,157,160,179,181,183,264,330,343,367,389,417],"both":[7],"MTC":[8,51,138,238,265,303,331,368,390,418],"&":[9,96,103,139,252,283,315,334,351,369,377,391],"RAIR":[10,63,148],"DTC.":[11,149,420],"However,":[12],"therapeutic":[13],"options":[14],"are":[15,422],"limited":[16],"after":[17,94],"disease":[18,328],"becomes":[19],"refractory":[20],"to":[21,59,99,258,289,424],"one":[22,313],"or":[23],"two":[24],"lines":[25,74],"of":[26,28,35,72,75,110,427],"standard":[27],"care":[29],"therapies.":[30],"We":[31],"report":[32],"here":[33],"results":[34],"an":[36],"investigator-initiated":[37],"phase":[38],"II":[39],"clinical":[40,409],"trial":[41,410,437],"evaluating":[42],"regorafenib":[43],"this":[45],"population":[46],"(NCT02657551).":[47],"Methods:":[48],"Patients":[49,301],"with":[50,91,302,306],"(disease":[52],"progression":[53,329],"within":[54,66],"6-12":[55],"months,":[56],"mo,":[57,383,405],"prior":[58,73,317,428],"study":[60],"registration)":[61],"and":[62,212,304,399,419,433],"DTC":[64,274,305,335,370,392],"(progression":[65],"12":[67],"mo)":[68],"were":[69,131,207,296,341,348,359,371,393],"enrolled":[70,208],"regardless":[71],"therapy.":[76],"Regorafenib":[77,408],"(each":[78,353],"cycle":[79,123],"3":[80],"weeks":[81,98],"ON/1":[82],"week":[83],"OFF)":[84],"was":[85,120,153,220,231,246,267,277,327],"started":[86],"at":[87,134,243,299],"80":[88],"mg":[89,101,105],"daily,":[90,106],"planned":[92,423],"escalation":[93],"1":[95],"2":[97,124],"120":[100],"daily":[102],"160":[104],"respectively,":[107],"absence":[109],"significant":[111],"treatment-related":[112,361],"adverse":[113],"events":[114],"(TRAEs).":[115],"The":[116,128,321],"highest":[117],"tolerated":[118],"dose":[119],"continued":[121],"from":[122],"onwards":[125],"until":[126],"progression.":[127],"primary":[129,415],"endpoints":[130,416],"proportion":[132,175,241],"progression-free":[133,159,242,364],"10":[135,244],"months":[136,245],"overall":[140,386],"response":[141,182],"rate":[142],"(ORR)":[143],"by":[144],"RECIST":[145],"v1.1":[146],"Simon":[150],"two-stage":[151],"design":[152],"utilized;":[154],"MTC:":[155],"<2":[156],"8":[158],"first":[161,184],"stage":[162,166,185,189],"stops":[163,186],"for":[164,174,187,197,325],"futility,":[165],"2:":[167,190],"enroll":[168,191],"13,":[169],">6/21":[170],"provides":[171,194],"81%":[172,195],"power":[173,196],">20%;":[176],"DTC:":[177],"<3":[178],"9":[180,205],"futility;":[188],"11,":[192],">7/20":[193],"ORR":[198,263,276],">25%.":[199],"Results:":[200],"17":[201],"patients":[202,295],"(8":[203],"MTC,":[204,216],"DTC)":[206],"between":[209],"April":[210],"2016":[211],"October":[213],"2022.":[214],"Among":[215,226],"median":[217,228],"(range)":[218,230],"age":[219,229],"54.7y":[221],"(48.1,":[222],"62.8),":[223],"25%":[224],"female.":[225,236],"DTC,":[227],"62.8y":[232],"(44.3,":[233],"75.8),":[234],"55.6%":[235],"In":[237,273],"group,":[239,275],"the":[240,256,287],"12.5%":[247,268],"(95%":[248,269,279,373,379,395,401],"CI":[249,270,280,374,380,396,402],"0.3%,":[250,271,281],"52.7%)":[251],"did":[253,284,411],"not":[254,285,412],"meet":[255,286],"criteria":[257,288],"continue":[259,290],"into":[260,291],"2nd":[261,292],"stage.":[262,293],"group":[266],"52.7%).":[272],"11.1%":[278],"48.2%),":[282],"No":[294],"receiving":[297],"treatment":[298],"cutoff.":[300],"objective":[307],"responses":[308],"(1":[309],"each)":[310],"had":[311],"received":[312],"(vandetanib)":[314],"no":[316,360],"systemic":[318],"therapy,":[319],"respectively.":[320,384,406],"most":[322,346],"common":[323],"reason":[324],"discontinuation":[326],"(4,":[332],"50%)":[333],"(5,":[336],"55.6%).":[337],"Grade":[338],"3-4":[339],"TRAEs":[340],"observed":[342],"8/17":[344],"(47.1%),":[345],"frequent":[347],"diarrhea,":[349],"hypophosphatemia,":[350],"hypertension":[352],"grade":[354],"3:":[355],"2,":[356],"11.7%).":[357],"There":[358],"deaths.":[362],"Median":[363,385],"survival":[365,387],"(PFS)":[366],"5.3":[372],"3.6,":[375],"20.1)":[376],"11.0":[378],"1.2,":[381],"24.0)":[382],"(OS)":[388],"16.1":[394],"5.2,":[397],"NA)":[398,404],"20.1":[400],"1.6,":[403],"Conclusions:":[407],"reach":[413],"its":[414],"Analyses":[421],"investigate":[425],"impact":[426],"VEGFR":[429],"inhibitor":[430],"exposure,":[431],"biomarkers":[432],"resistance":[434],"mechanisms.":[435],"Clinical":[436],"information:":[438],"NCT02657551":[439],".":[440],"[Table:":[441],"see":[442],"text]":[443]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2024-07-24T00:00:00"}